Clear Cell Carcinoma of the Ovary with Choriocarcinomatous Differentiation- A Rare Aggressive Tumour

Varsha Ginnavaram, Vasugi Gramani Arumugam*, Sandhya Sundaram, Swaminathan Rajendiran, Lawrence D’cruze

Department of Pathology, Sri Ramachandra Medical College, Chennai, Tamilnadu, India

*Corresponding author: Dr. Vasugi Gramani Arumugam

INTRODUCTION

Ovarian carcinomas may produce human chorionic gonadotropin (HCG) or HCG-like substances and may even contain syncytiotrophoblast cells, but a true choriocarcinomatous component has not been described in these tumors.

CASE REPORT

We report a case of a 54-year-old woman who presented with weight loss of 10 kg. She attained menopause at the age of 45 years. There was no postmenopausal bleeding. Clinical examination showed an irregular hard pelvic mass extending up to the umbilicus. A computed tomography (CT) showed a heterogeneous irregular mass measuring 14x12x8cm in the central pelvic cavity with gross ascites. Radiologically (Fig-1) the mass showed solid and cystic areas and a diagnosis of complex ovarian cyst favouring malignancy was rendered. The mass was excised in toto and sent for histopathological examination. Grossly, we received a salpingo-oophorectomy specimen measuring 13x11x8 cm. External surface was smooth with congested blood vessels. Cut surface revealed solid (40%) and cystic (60%) areas and reddish brown fluid was extruded. Friable and hemorrhagic areas were noted grossly. Microscopy revealed sheets of clear cells the lesion was composed of round to oval cells with ill defined cell border, moderate eosinophilic to clear cytoplasm and bland nuclei. A panel of Immunohistochemical markers were performed and the lesional cells were positive for Pax 8 (Fig 4) and beta HCG. (Fig 5) With H&E morphology and Immunohistochemical staining pattern a diagnosis of clear cell carcinoma of the ovary with choriocarcinomatous differentiation was rendered.

Table-1: Panel of Immunohistochemical Markers

<table>
<thead>
<tr>
<th>IHC MARKERS</th>
<th>INFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pax 8</td>
<td>Positive in clear cells</td>
</tr>
<tr>
<td>HCG</td>
<td>Positive in syncytiotrophoblast like cells</td>
</tr>
</tbody>
</table>

Keywords: Choriocarcinomatous differentiation, Pax-8, Beta HCG.
Fig 1: CT pelvis showing solid and cystic mass in right adnexa

Fig 2: Gross image showing cystic ovarian mass with solid areas (40%)

Fig 3a: (H&E x100) cystic area lined by atypical clear cells

Fig 3b: (H&E x200) cells showing hobnailing

Fig 3c: (H&E x200) solid areas showing sheets of clear cells admixed with giant cells simulating syncytiotrophoblast

Fig 3d: (x400), solid areas showing sheets of clear cells admixed with giant cells simulating syncytiotrophoblast

Fig 3e: (x400): solid areas showing sheets of clear cells admixed with giant cells simulating syncytiotrophoblast
DISCUSSION

Choriocarcinoma is a malignant tumor that may present as one end of the spectrum of gestational trophoblastic disease or as a component of a germ cell tumor. Alternately, choriocarcinomatous differentiation has been sporadically described in extragenital tumors, particularly in gastric adenocarcinomas, but in carcinomas from other organs as well, such as lung, esophagus, small bowel, colon, breast, prostate, liver, pelvis, and urinary bladder [1-4]. Carcinomas with trophoblastic differentiation are also rare in the female genital tract.

Civantos and Rywin [5] and Barua and Richmond [6] respectively, reported three ovarian carcinomas containing anaplastic foci with numerous HCG-positive multinucleated cells and one ovarian carcinosarcoma with isolated trophoblast cells. Various hypotheses have been postulated to explain the histogenesis of this peculiar association. Whereas some authors favor a divergent differentiation [7] or even a process of "neometaplasia" [8, 9], the theory of "retrodifferentiation" or "dedifferentiation" appears to be the most acceptable. It attributes this phenomenon to the multipotentiality of the somatic cells, the differentiation of which is a consequence of repression or expression of distinct genes. During carcinogenesis, tumor cells may recuperate morphologic features or functional properties they already had during early embryologic development that are later suppressed under normal conditions [10]. HCG is an oncofetal antigen detectable in fetal tissues as well as in various tumors, with and without SCT cells. It is usually absent in normal adult tissues [11] and its production by tumor cells has been thought to be related to gene “derepression.”

An extreme form of trophoblastic differentiation in nongerm cell carcinomas is the development of a true choriocarcinoma in which the malignant cytotrophoblasts and syncytiotrophoblasts grow in a bilaminar or plexiform pattern intermixing with the somatic malignancy. Most choriocarcinomas of the ovary are usually gestational, and are metastases from a uterine or a tubal choriocarcinoma, and rarely as a complication of an ovarian pregnancy. Nongestational choriocarcinomas of the ovary, which are more often a component of mixed germ cell tumors, represented 20% of such cases in one case series, they are usually found in prepubertal patients.

Pure nongestational choriocarcinomas are exceedingly rare, accounting for less than 1% of primitive germ cell tumors of the ovary. The presence of choriocarcinoma with a somatic epithelial malignancy of nongerm cell origin is most unusual, with only 5 documented cases found in the literature (Table-1). The age of the patients with ovarian epithelial tumors with choriocarcinomatous differentiation ranged from 33 to 63 years (mean, 51 and median, 51.5). Our patient was also postmenopausal. The presenting complaints were abdominal distention, pelvic mass, pain, or combinations thereof.

The presence of a CC component within an otherwise typical ovarian epithelial tumor results in a very aggressive tumor with early metastasis and high-stage disease at presentation as exemplified by this case. Five of the 6 reported cases, including ours, were assigned FIGO stage IV at the time of diagnosis (Table-2). All but 1 patient died from the disease between 0 to 15 months (mean, 8.6 and median, 10) after the diagnosis was made.
CONCLUSION
In conclusion, we have described the clinicopathologic features of an ovarian clear cell carcinoma with choriocarcinomatous differentiation. Our findings are in keeping with earlier reports, confirming that carcinomas with choriocarcinomatous differentiation behave aggressively. Patients with such tumors are more commonly postmenopausal, have high-stage disease at presentation, and poor survival. Nonetheless, our experience with this case suggests that neoadjuvant chemotherapy targeting at both the epithelial and CC components may offer a new treatment option in reducing the volume of the disease and facilitate debulking surgery. Further experience with different chemotherapy regimes is needed before an effective treatment can be determined.

REFERENCES

Table 2: Similar Case Reports in Literature

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient details</th>
<th>Epithelial component</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oliva et al., case 1 [12]</td>
<td>59/F</td>
<td>Undifferentiated carcinoma</td>
<td>TAHBSO; followed by adjuvant carboplatin, methotrexate and cyclophosphamide</td>
</tr>
<tr>
<td>Oliva et al., case 2 [12]</td>
<td>33 /F</td>
<td>No Mucinous cystadenoma</td>
<td>cisplatin-based chemotherapy; changed to multiagent chemotherapy (dactinomycin, etoposide, cyclophosphamide and doxorubicin) for the progressive disease</td>
</tr>
<tr>
<td>Ozaki et al., [13]</td>
<td>53/F</td>
<td>Mucinous cystadenoma</td>
<td>TAHBSO</td>
</tr>
<tr>
<td>Jimenez-Heffernan et al., [14]</td>
<td>63/F</td>
<td>Mucinous cystadenocarcinoma</td>
<td>TAHRSO, LND; followed by adjuvant cisplatin (IP); carboplatin &amp; paclitaxel; changed to EP-EMA for progressive disease</td>
</tr>
<tr>
<td>Hirabayashi et al., [15]</td>
<td>50/F</td>
<td>Clear cell, small cell, and endometrioid adenocarcinoma</td>
<td>Neoadjuvant etoposide and cisplatin, switched to TE/TC, followed by TAHBSO, omentectomy and tumor debulking; and additional TE/TC, and gemcitabine/taxotere</td>
</tr>
<tr>
<td>Yuan Jing Hu et al., [16]</td>
<td>48/F</td>
<td>Clear cell carcinoma</td>
<td>Salpingoopherectomy followed by second line chemotherapy</td>
</tr>
<tr>
<td>Current case</td>
<td>54/F</td>
<td>Clear cell carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

© 2020 Published by Scholars Middle East Publishers, Dubai, United Arab Emirates 196


